Skip to main content
    K

    Kura Oncology Inc (KURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.49
    +0.40 (+5.64%)

    Market Cap: $713.90M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Kura Oncology Inc (KURA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Kura Oncology (KURA) has a market cap of $713.90M and an enterprise value of $665.79M. It kept -369.26% of revenue as net income over the last 12 months. Revenue fell 23.76% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 6.74% below the market cap, as cash exceeds debt.

    Market Cap$713.90M
    Enterprise Value$665.79M
    Latest price (Nov 17, 2026)$7.49

    Key Dates

    The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 3, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.08% in the quarter ended Sep 30, 2026 and grew 1.64% a year over 2 years.

    Shares Outstanding89.82M
    Shares Change (YoY)+2.48%
    Shares Change (QoQ)+1.08%
    Share Count Growth (2Y CAGR)+1.64%

    Valuation Ratios

    Sales and book value multiples are 8.5x and 37.5x. Its year-end P/S ranged from 13.5x to 875.7x from 2018 to 2025.

    P/S Ratio8.5x
    Forward P/S7.6x
    P/B Ratio37.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 33.15% over 52 weeks and trades 24.72% below its 50-day average.

    Beta (1Y)1.36
    52-Week Change-33.15%
    1-Month Change-19.98%
    3-Month Change-40.22%
    6-Month Change-16.41%
    5-Year Change-37.52%
    10-Year Change+153.33%
    Total Return (1Y)-33.15%
    Total Return (3Y CAGR)-7.81%
    Total Return (5Y CAGR)-15.38%
    Return vs SPY (1Y)-43.96%
    Max Drawdown (1Y)-49.96%
    Max Drawdown (3Y)-76.46%
    Sharpe Ratio (1Y)-0.61
    Correlation with SPY (1Y)0.29
    50-Day Average$9.95
    200-Day Average$9.77
    52-Week Range$6.75 to $13.90
    RSI (14 Days)37.4
    Average Volume (20 Days)2.47M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.60x current liabilities, and total debt is 0.55x shareholder equity.

    Current Ratio3.60x
    Quick Ratio3.56x
    Debt / Equity0.55x
    Interest Coverage-227.12x

    Returns and Efficiency

    Return on invested capital is -1125.29% over the last 12 months, against a 5-year average of -81.01%.

    Return on Equity (ROE)-1630.70%
    Return on Assets (ROA)-51.70%
    Return on Invested Capital (ROIC)-1125.29%
    ROE (5Y Average)-59.72%
    ROA (5Y Average)-29.77%
    ROIC (5Y Average)-81.01%
    Asset Turnover0.13x
    Inventory Turnover0.25x
    Receivables Turnover6.63x
    Cash Conversion Cycle-542 days

    Scores

    KURA has an Altman Z-Score of -3.55, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-3.55
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $79.31M over the last 12 months.

    Revenue$79.31M
    Revenue Growth (YoY)-23.76%
    Gross Profit$78.38M
    Operating Income-$312.75M
    Pretax Income-$292.79M
    Net Income-$292.87M
    Reported EPS (TTM)-$3.30

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 3.17% of the $566.50M in total assets.

    Cash and Equivalents$57.94M
    Total Debt$9.83M
    Net Cash$48.10M
    Net Cash Per Share$0.54
    Working Capital$385.97M
    Shareholder Equity$17.96M
    Book Value Per Share$0.20
    Total Assets$566.50M
    Total Liabilities$548.54M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $3.55M of capital spending, operating cash flow left -$89.12M of free cash flow.

    Operating Cash Flow-$85.57M
    Capital Expenditures$3.55M
    Free Cash Flow-$89.12M
    FCF Per Share-$1.00
    Depreciation and Amortization$4.68M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -394.32%.

    Gross Margin98.82%
    Operating Margin-394.32%
    Pretax Margin-369.15%
    Net Margin-369.26%
    FCF Margin-112.37%

    Growth

    Book Value Per Share Growth (2Y CAGR)-37.95%
    Tangible Book Per Share Growth (2Y CAGR)-37.95%

    Revenue and profit by year

    Dividends and Yields

    KURA does not pay a dividend. Its free cash flow yield is -13.25%.

    FCF Yield-13.25%
    Buyback Yield-5.24%
    Shareholder Yield-5.24%

    Peer Position

    Against 5 similar companies, KURA has the 3rd highest P/S.

    P/S Ratio8.5x vs 7.7x median
    ROIC-1125.29% vs -25.72% median
    Revenue Growth (Trailing 4 Quarters, YoY)-23.76% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 72.33% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+72.33%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About KURA

    What is KURA's market cap?

    Kura Oncology has a market cap of $713.90M. Its enterprise value, which adds debt and subtracts cash, is $665.79M.

    How many shares of KURA are outstanding?

    Kura Oncology has 89.82M shares outstanding. The count is up 2.48% from a year earlier.

    Does KURA pay a dividend?

    No. Kura Oncology does not pay a dividend.

    How much debt does KURA have?

    Kura Oncology has $9.83M of total debt and $57.94M of cash and equivalents, a net cash position of $48.10M.